The usage of laferon in treatment of patients with community acquired pneumonia (CAP)

I. Ilyuk, S. Nechiporuk (Vinnitsa, Ukraine)

Source: Annual Congress 2007 - Miscellaneous lower respiratory tract infections
Session: Miscellaneous lower respiratory tract infections
Session type: Thematic Poster Session
Number: 3924
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Ilyuk, S. Nechiporuk (Vinnitsa, Ukraine). The usage of laferon in treatment of patients with community acquired pneumonia (CAP). Eur Respir J 2007; 30: Suppl. 51, 3924

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The usage of thiotriazolin in complex treatment of patients with community acquired pneumonia
Source: Eur Respir J 2005; 26: Suppl. 49, 579s
Year: 2005

Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France
Source: Eur Respir J 2003; 22: Suppl. 45, 151s
Year: 2003

Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP)
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007


Improving outcome in elderly patients with pneumonia
Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI
Year: 2005

Using roncoleukine in basic therapy of patients with community acquired pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 443s
Year: 2002

Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008


Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP)
Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests
Year: 2008


Progress of quality indicator rates regarding treatment of patients hospitalized in Germany due to community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010

Therapeutic regimens in community acquired pneumonia (CAP): association with patients characteristics and outcomes
Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests
Year: 2008


Relevance of correct antibiotic choice in community-acquired pneumonia (CAP)
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005


Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease
Source: International Congress 2019 – M-health/e-health I
Year: 2019


The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006

Biological markers in hospitalised patients with community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010

The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006

Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012

Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006

Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006

Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011


A prospective comparison of nursing home acquired pneumonia (NAP) with community acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 257s
Year: 2005

Cardiac diseases in patients with community acquired pneumonia (CAP)
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012